Filtered By:
Specialty: Pharmaceuticals
Nutrition: Sugar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 8 results found since Jan 2013.
Positive Phase III results for Roche ’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis
Phase III OCARINA II trial met primary and secondary endpointsOCREVUS twice a year, 10-minute injection has the potential to further improve the treatment experience and expand OCREVUS usage in MS centres with IV capacity limitations or without IV infrastructureOCREVUS remains the first and only therapy approved for both RMS and PPMS, and more than 300,000 people have been treated globallyBasel, 13 July 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III OCARINA II trial evaluating OCREVUS ® (ocrelizumab) as a twice a year 10-minute subcutaneous injection met its primary and secondary endpoints in...
Source: Roche Media News - July 13, 2023 Category: Pharmaceuticals Source Type: news
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
Diabetes is a scary diagnosis for anyone. When people with the disease struggle to manage their blood sugar levels, they can experience significant, life-threatening and costly complications such as heart attack, stroke, kidney failure, amputation and blindness. Fortunately, diabetescan be well-managed with comprehensive access to health care services, including medicines.
Source: The Catalyst - May 25, 2023 Category: Pharmaceuticals Authors: Reid Porter Tags: Diabetes Adherence Medicaid Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Sugar-Sweetened Beverages May Increase Risk for CVD in Women
WEDNESDAY, May 13, 2020 -- Sugar-sweetened beverage (SSB) consumption is associated with an increased risk for cardiovascular disease (CVD), revascularization, and stroke among women, according to a study published online May 13 in the Journal of...
Source: Drugs.com - Pharma News - May 13, 2020 Category: Pharmaceuticals Source Type: news
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific Session
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to Tweet: Jan...
Source: Johnson and Johnson - March 20, 2020 Category: Pharmaceuticals Source Type: news
Why Eating Slowly This Thanksgiving Will Improve Your Long-Term Health
As you sit down to Thanksgiving dinner to partake of turkey with all the trimmings, it ’s best to eat slowly. The risk includes not only weight gain, and elevated blood sugar, but your odds of developing metabolic syndrome, which can increase your risk of heart attack, stroke, and diabetes.
Source: Forbes.com Healthcare News - November 23, 2017 Category: Pharmaceuticals Authors: Robert Glatter, MD, Contributor Source Type: news
Why Eating Slowly This Thanksgiving Will Improve Your Long Term Health
As you sit down to Thanksgiving dinner to partake of turkey with all the trimmings, it ’s best to eat slowly. The risk includes not only weight gain, and elevated blood sugar, but your odds of developing metabolic syndrome, which can increase your risk of heart attack, stroke, and diabetes.
Source: Forbes.com Healthcare News - November 23, 2017 Category: Pharmaceuticals Authors: Robert Glatter, MD, Contributor Source Type: news
